Evidence map›Paper›PMID 11322501›Full record

ReviewEndocrine2001

Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

J D Veldhuis, W S Evans, C Y Bowers, S Anderson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 27 citations in OpenAlex.

  1. Estroprogestinic pill normalizes IGF-I levels in acromegalic women.Journal of endocrinological investigation · 2003
    Trial
  2. Article
  3. Review
  4. Human GH pulsatility: an ensemble property regulated by age and gender.Journal of endocrinological investigation · 2003
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

J D VeldhuisDepartment of Internal Medicine, General Clinical Research Center, University of Virginia School of Medicine, Charlottesville 22908-0202, USA. jdv@virginia.edu
W S Evans
C Y Bowers
S Anderson
University of Virginia · USTulane University · US

Funding

ZACOPRIDE VS METOCLOPRAMIDE--EFFECT ON LOWER ESOPHAGEAL SPHINCTERM01RR000847 · NCRR · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HEWLETT, ERIK L · 1985 to 2010
$48.1M
PROJECT 3 - Steroid-Metabolic Interactions In the Control of GnRH NeuronsU54HD028934 · NICHD · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI MCCARTNEY, CHRISTOPHER ROLLAND · 1998 to 2013
$16.5M
NCRR NIH HHS MO1 RR00847NICHD NIH HHS U-54 HD28934
6 · The paper itself

Abstract

Estrogen is the proximate sex steroid sustaining GH secretion throughout the human life span in both sexes. However, very little is known about the specific neuroendocrine mechanisms by which estrogen activates and maintains GH secretion in the young or aging human. The identification of somatostatin in 1973 as a key negative peptidyl regulator of the GH axis and the discovery of GH-releasing hormone (GHRH) in 1982 as a dominant feedforward agonist of GH secretion provided an initial basic science foundation for exploring sex-steroid control of the GH-IGF-1 axis. Although GH-releasing peptides (GHRPs) were first recognized in 1977-1981, subsequent cloning of hypothalamopituitary receptors transducing potent secretagogue actions of GHRPs in 1996 and of an endogenous ligand for this effector pathway in 1999 now extend the framework for examining the mechanisms of estrogen-driven GH secretion in aging. Herein, we review several novel and multifaceted interactions in postmenopausal women between estrogen and GHRP-2. We combine these observations into a simplified construct of GH-axis neuroregulation comprising the somatostatin, GHRH, and GHRP effector pathways, as well as GH and IGF-1 autofeedback. We suggest the thesis that estrogen controls the interfaces among these pivotal regulatory peptides in hyposomatotropic postmenopausal individuals.

Indexed as

PostmenopauseClinical Trials as TopicDose-Response Relationship, DrugEstradiolEstrogensFeedbackFemaleGrowth HormoneHumansHypothalamusInsulin-Like Growth Factor IModels, ChemicalOligopeptidesSomatostatinUp-RegulationEstradiolEstrogensGrowth Hormonegrowth hormone-releasing peptide-2Insulin-Like Growth Factor IOligopeptidesSomatostatin

Identifiers

PMID11322501
OpenAlexW2044059980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.